

Uta Bertsch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/279582/publications.pdf>

Version: 2024-02-01

22
papers

412
citations

932766

10
h-index

794141

19
g-index

23
all docs

23
docs citations

23
times ranked

552
citing authors

#	ARTICLE	IF	CITATIONS
1	Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. <i>Journal of Clinical Oncology</i> , 2022, 40, 3406-3418.	0.8	115
2	Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 1.	2.8	57
3	Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. <i>Leukemia</i> , 2020, 34, 1853-1865.	3.3	47
4	Selective elimination of immunosuppressive T cells in patients with multiple myeloma. <i>Leukemia</i> , 2021, 35, 2602-2615.	3.3	27
5	A systematic classification of death causes in multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 30.	2.8	26
6	Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. <i>BMC Cancer</i> , 2019, 19, 504.	1.1	25
7	Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial. <i>Blood</i> , 2021, 138, 463-463.	0.6	19
8	Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment. <i>Cancers</i> , 2020, 12, 2322.	1.7	15
9	Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial. <i>Haematologica</i> , 2016, 101, e485-e487.	1.7	14
10	Longitudinal fluorescence <i>in situ</i> hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation. <i>Haematologica</i> , 2017, 102, 1432-1438.	1.7	14
11	The prognostic significance of [18F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPETUs). <i>EJNMMI Research</i> , 2021, 11, 100.	1.1	12
12	Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison. <i>Immunotherapy</i> , 2021, 13, 143-154.	1.0	9
13	Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 71.	2.8	7
14	Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age. <i>Leukemia</i> , 2021, 35, 809-822.	3.3	7
15	Angiogenic Signature of Multiple Myeloma Determined by Gene Expression Profiling. <i>Blood</i> , 2007, 110, 2484-2484.	0.6	7
16	Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial. <i>Leukemia</i> , 2021, 35, 3007-3011.	3.3	4
17	Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up. <i>Blood</i> , 2019, 134, 3308-3308.	0.6	3
18	Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2015, 126, 4233-4233.	0.6	2

#	ARTICLE	IF	CITATIONS
19	MCT1 As Molecularly Validated Predictive Marker for Lenalidomide-Maintenance Therapy in Multiple Myeloma. Blood, 2019, 134, 3187-3187.	0.6	1
20	Subcutaneous Versus Intravenous Bortezomib in Two Different Induction Therapies for Newly Diagnosed Multiple Myeloma – Subgroup Analysis from the GMMG-MM5 Trial. Blood, 2014, 124, 3475-3475.	0.6	1
21	Profound Impact of Sample Processing Delay on Gene Expression of Multiple Myeloma Plasma Cells. Blood, 2015, 126, 2996-2996.	0.6	0
22	Impact of Severe Infections during Induction Therapy on Dosage, Response and Survival in Newly Diagnosed Multiple Myeloma - a Subgroup Analysis from the Randomized Phase III Trial GMMG-HD4. Blood, 2015, 126, 3187-3187.	0.6	0